Abstract 497P
Background
The EGFRm rate in metastatic NSCLC is 30%∼40% in China. Osimertinib, 3rd generation EGFR-TKI, is approved as the 1st line treatment for patients with advanced EGFRm NSCLC and 2nd line treatment for patients with EGFR T790M positive advanced NSCLC globally, and only is approved as the 2nd line treatment in China by now. This study is to investigate the efficacy of Osimertinib in patients with metastatic EGFRm NSCLC in the real word clinical setting in China.
Methods
This multi-center study was conducted in 13 medical centers in China from April 2017 to May 2019 (Clinical trial ID: 1800019903). Patients with metastatic EGFRm NSCLC received by Osimertinib were enrolled into this study. All data were collected and analyzed on China Multi-center Lung Cancer Precision Medicine Registry RWE Box.
Results
A total of 346 patients with metastatic EGFRm NSCLC were enrolled in this study (female: 56.5%, male: 43.5%). 95.1% patients were adenocarcinoma, 2.3% patients were squamous carcinoma and 1.7% patients were adenosquamous carcinoma. The percentage of Osimertinib as 1st line, 2nd line, 3rd line, and more than 3rd line therapy was 10.4%, 55.8%, 21.4% and 12.6%, respectively. 42.5% patients were identified as the secondary T790M (+)after failure of the 1st line EGFR-TKI. For patients (N = 145) with T790M (+) metastatic NSCLC treated by Osimertinib as 2nd line therapy, the ORR was 75.1%, the mPFS was 276 days. Subgroup analysis showed that for those with both T790M (+) and CNS metastasis (N = 146), the mPFS was 280 days and CNS ORR was 67.2%. Interestingly, the CNS ORR was 34.4% for those with T790M (-) of CNS metastasis. In patients (N = 193) who had progressed after 2nd line Osimertinib, 78.9% received chemotherapy, 13.4% received bevacizumab combined with chemotherapy, and 7.7% received immunotherapy, respectively.
Conclusions
Osimertinib was generally used as 2nd line treatment in patients who were resistance to the 1st line EGFR-TKI in China. Real-word data further demonstrated and validated the similar efficacy of Osimertinib as 2nd line therapy in China as that previously reported clinical trials.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
303P - Segmental mandibulectomy without reconstruction
Presenter: Yohei Morishita
Session: Poster display session
Resources:
Abstract
304P - Survival outcomes and survival predictors in recurrent and metastatic head and neck squamous cell cancer (R/M-HNSCC) patients treated with chemotherapy (CT) plus cetuximab as first-line therapy in a real-world study
Presenter: Filipa Pontes
Session: Poster display session
Resources:
Abstract
305P - A retrospective study to evaluate patient characteristics for recurrent head and neck cancer after definitive treatment
Presenter: Tetsuro Wakasugi
Session: Poster display session
Resources:
Abstract
306P - Efficacy and safety of apatinib in heavily pretreated metastatic adenocarcinoma of the head and neck
Presenter: Lin Gui
Session: Poster display session
Resources:
Abstract
307P - Lacrimal gland tumours: Clinical and epidemiological patterns in the United States
Presenter: Mahmoud KhalafAllah
Session: Poster display session
Resources:
Abstract
308P - Dental prophylaxis and 5-fluorouracil related oral mucositis in head and neck cancer patients: A population-based cohort study
Presenter: Yi-Fang Huang
Session: Poster display session
Resources:
Abstract
309P - Evaluation of a pharmacist-led opioid de-escalation (PLODE) program after chemoradiotherapy completion in head and neck cancer patients
Presenter: Ai Horinouchi
Session: Poster display session
Resources:
Abstract
310P - Laser and PDT for the oral leukoplakia
Presenter: Sadykov Rasul
Session: Poster display session
Resources:
Abstract
311P - Incidence of thyroid carcinoma in the Philippines: A retrospective study from a tertiary university hospital
Presenter: Priscilla Caguioa
Session: Poster display session
Resources:
Abstract
312P - Oral health disparities among privileged and underprivileged tribes of south India - A study on precancerous oral lesions prevalence
Presenter: Shanavas Palliyal
Session: Poster display session
Resources:
Abstract